Business Daily from THE HINDU group of publications
Friday, Apr 20, 2007
ePaper


News
Features
Stocks
Cross Currency
Shipping
Archives
Google

Group Sites

Industry & Economy - Pharmaceuticals
Marketing - Piracy
PIL on spurious drugs: `Implement Mashelkar panel recommendations'

P.T. Jyothi Datta

Thrust to implement Mashelkar Committee recommendations

Mumbai April 19 A Public Interest Litigation (PIL) on spurious drugs has been filed in the Delhi High Court, asking the Government to implement recommendations made by the Mashelkar Committee in an earlier report.

The PIL, filed in an individual capacity by Mr Harinder Sikka of drug-maker Nicholas Piramal India Ltd, was heard on Wednesday and admitted, Mr Sikka told Business Line.

Though the Centre accepted the recommendations made by the Mashelkar Committee over three years ago, it has not been able to implement them yet, he pointed out.

The PIL has also asked the Government to replace the L1 system of tendering and give preference to quality while procuring medicines, rather than considering proposals that offered the lowest price. Because of the L1 system, large drug companies do not participate in tenders, Mr Sikka said.

Concerns over the prevalence of spurious drugs in the country had peaked in 2003, when the death penalty had been mooted by then Union Health Minister, Ms Sushma Swaraj. But the Bill proposing the death penalty lapsed as the National Democratic Alliance (NDA) Government got unseated at the Centre.

The death penalty has since been converted into a life sentence by the subsequent United Progressive Alliance (UPA) coalition. Other penalties that the Union Health Ministry proposed included increasing the fine amount and making the offence cognisable and non-bailable.

There are still no numbers available to indicate the prevalence of spurious drugs in India. Earlier industry estimates of spurious drugs being one in every four medicines sold in the country and accounting for a revenue loss of Rs 4,000 crore were trashed by the Centre when the Mashelkar Committee had submitted its interim report in 2003.

Spurious drugs are found in different parts of the country including Delhi, the PIL said, and across therapeutic segments, from painkillers like paracetamols to fake insulin and chemotherapy drugs.

Some of the recommendations suggested by the Mashelkar Committee in its final report in November 2003 included designating a special court for speedy trial of spurious drugs cases.

"However, more than three years after the date of the said Report, none of its recommendations have been implemented," the PIL said.

More Stories on : Pharmaceuticals | Piracy | Courts/Legal Issues | Economic Offences

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page



Stories in this Section
Increased reliance on CRR — No point blaming the RBI


No relief from high edible oil prices
In the dumps
Govt lends a hand to exports
Chambers welcome Foreign Trade Policy
Danish cos see business opportunities in Bengal
Govt rules out private role in KMML
Uzbekistan agrees to talks with GAIL for gas exploration
PIL on spurious drugs: `Implement Mashelkar panel recommendations'
`Cuddalore Power will sell electricity at Rs 2.30 a unit'
Apparel parks will be set up in three centres
RBI redefines micro, small, medium enterprises
Govt wants more credit support to small exporters
NIOT demonstrates floating desalination project
Star exporter status norms reviewed
`Export infrastructure must be strengthened'
Govt outlines steps for cutting transaction cost
India Inc welcomes foreign trade policy supplement
Nod for amendment to Boilers Act
Dr Lal PathLabs plans laboratory for clinical research
CII team confers with YSR
SIEMA wants abolition of customs duty on copper
Tirupur exporters' body hails export policy
Fund to plug power sector investment gap likely
Amul-Tata Fellowships to continue
Alleged violation of wage accord by company
Non-basmati rice exports may touch 40 lakh tonnes
Validity of import regime for metal scrap extended
Export target revised over rising rupee


The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | The Hindu ePaper | Business Line | Business Line ePaper | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright © 2007, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line